Zenas Biopharma Inc
NASDAQ:ZBIO

  • LAST PRICE
    19.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    18.8500/ 4
  • Ask / Lots
    19.2400/ 4
  • Open / Previous Close
    19.4000 / 19.0000
  • Day Range
    17.5200
    20.1325
  • 52 Week Range
    17.0200
    20.1325
  • Volume
    82,879

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 19, 2024

      Show headlines and story abstract

    • 4:15PM ET on Thursday Sep 19, 2024 by Dow Jones
      Companies Mentioned: ZBIO

      Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

      WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of its common stock, which closed on September 16, 2024, exercised in full their option to purchase an additional 1,985,294 shares at the initial public offering price of $17.00 per share. After giving effect to the full exercise of the underwriters' option to purchase additional shares, which closed on September 19, 2024, Zenas sold 15,220,588 shares in its initial public offering, resulting in gross proceeds of approximately $258.7 million. All of the shares were sold by Zenas. Zenas' shares began trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol "ZBIO".

    • 4:15PM ET on Thursday Sep 19, 2024 by Dow Jones
      Companies Mentioned: ZBIO

      WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of its common stock, which closed on September 16, 2024, exercised in full their option to purchase an additional 1,985,294 shares at the initial public offering price of $17.00 per share. After giving effect to the full exercise of the underwriters' option to purchase additional shares, which closed on September 19, 2024, Zenas sold 15,220,588 shares in its initial public offering, resulting in gross proceeds of approximately $258.7 million. All of the shares were sold by Zenas. Zenas' shares began trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol "ZBIO".

  • Sep 13, 2024

Peers Headlines